Y
Yue Shentu
Researcher at Merck & Co.
Publications - 17
Citations - 12143
Yue Shentu is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Docetaxel. The author has an hindex of 10, co-authored 15 publications receiving 9368 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S. Herbst,Paul Baas,Dong Wan Kim,Enriqueta Felip,Jose Luis Perez-Gracia,Ji Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Gilberto de Castro,Marcelo Garrido,Gregory M. Lubiniecki,Yue Shentu,Ellie Im,Marisa Dolled-Filhart,Edward B. Garon +18 more
TL;DR: In this article, the authors evaluated the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Journal ArticleDOI
Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
Luis Paz-Ares,Alexander Luft,Ali Tafreshi,Mahmut Gumus,Julien Mazieres,Barbara Hermes,Filiz Çay Şenler,Andrea Fülöp,Jerónimo Rodríguez-Cid,Shunichi Sugawara,Ying Cheng,Silvia Novello,Balazs Halmos,Yue Shentu,Dariusz M. Kowalski +14 more
TL;DR: Pembro plus pemetrexed and carboplatin resulted in superior objective response rate, progression-free survival (PFS) and overall survival (OS) for untreated pts with non-sq NSCLC, so combining with chemo is a rational next step.
Journal ArticleDOI
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
Roy S. Herbst,Paul Baas,Jose Luis Perez-Gracia,Enriqueta Felip,Dong Wook Kim,J-Y. Han,Julian R. Molina,Joo Hang Kim,C. Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Veerle Surmont,G. De Castro,Marcelo Garrido,Yue Shentu,Kenneth Emancipator,A. Samkari,Erin Jensen,Gregory M. Lubiniecki,Edward B. Garon +20 more
TL;DR: Pembrolizumab continued to improve OS over docetaxel in intention to treat population and in subsets of patients with newly collected and archival samples.
Journal ArticleDOI
Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.
Julie R. Brahmer,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csoszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Jessica McLean,Yue Shentu,Reshma A. Rangwala,Martin Reck +17 more
TL;DR: PFS2 and updated OS are presented, finding pembrolizumab (pembro) was superior to chemotherapy (chemo) as first-line (1L) therapy for advanced NSCLC with PD-L1 TPS ≥50% and no sensitizing EGFR mutations or ALK translocations.